








(IN380926)
Novel rhodamine B
amides and processes for
preparing the same







NEED

The search for effective diagnostic and therapeutic agents in oncology has led to innovations in fluorescent compounds. A breakthrough in rhodamine B heterocyclic amides offers novel opportunities for cancer diagnosis and treatment.

TECHNOLOGY OVERVIEW

This invention introduces novel rhodamine B heterocyclic amides, designed for fluorescence-based detection of malignancies. These compounds also show potential in treating cancer, offering enhanced diagnostic accuracy and targeted therapeutic benefits in oncology.

TECHNOLOGY KEY FEATURES

Rhodamine B heterocyclic amides, used in nanoparticle form, emit fluorescence for cancer detection and treatment. The compounds are tailored with various amine groups, allowing for customization in medical applications.

MARKET ANALYSIS

The global oncology diagnostics market is projected to grow at a CAGR of 8.2%, reaching \$50B by 2033 (source: Market Research Future). Increasing cancer incidence and demand for targeted therapies are major growth drivers.

Target Industries

1) Pharmaceutical companies developing cancer diagnostics, 2) Biotech firms focusing on fluorescence-based therapeutics, 3) Research institutions working on novel cancer treatments.

AT A GLANCE

 SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure)

Read more here

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913

